Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, announced the expansion of FLAMINGO-01 clinical trial to Austria. The company’s application to European regulators has been formally approved, adding Austria as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania, Ireland, Portugal, Belgium, and the U.S.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLSI:
- Greenwich LifeSciences expands Flamingo-01 clinical trial to Belgium
- Greenwich LifeSciences adds Portugal to Flamingo-01 clinical trial
- Greenwich LifeSciences expands Phase 3 Flamingo-01 clinical trial to Ireland
- Greenwich LifeSciences granted Fast Track designation for GLSI-100 by FDA
- Greenwich LifeSciences initiated with an Outperform at Noble Capital